FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 191, Issue -, Pages 104139
Publisher
Elsevier BV
Online
2023-09-16
DOI
10.1016/j.critrevonc.2023.104139
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2023) Harry P Erba et al. LANCET
- Advances in acute myeloid leukemia differentiation therapy: A critical review
- (2023) Amal Kamal Abdel-Aziz BIOCHEMICAL PHARMACOLOGY
- FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial
- (2022) E Dianne Pulte et al. ONCOLOGIST
- The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms
- (2022) Timothy T. Ferng et al. MOLECULAR CANCER THERAPEUTICS
- Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD+ AML Cells
- (2022) Panpan Feng et al. Frontiers in Cell and Developmental Biology
- Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy
- (2022) Eunice S. Wang et al. BLOOD
- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)
- (2022) Romain Sechaud et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- (2022) Naval Daver et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to targeted therapies: delving into FLT3 and IDH
- (2022) Sai Prasad Desikan et al. Blood Cancer Journal
- “FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
- (2022) Tristan E. Knight et al. Cancers
- Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
- (2022) Dominique A. Garrison et al. MOLECULES
- Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
- (2022) Melisa Tecik et al. OncoTargets and Therapy
- Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukaemia
- (2021) Stefan Bjelosevic et al. Cancer Discovery
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
- (2021) Laura Katharina Schmalbrock et al. BLOOD
- FDA Approval Summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation
- (2021) E. Dianne Pulte et al. CLINICAL CANCER RESEARCH
- OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
- (2021) Bartholomew J. Eisfelder et al. Blood Cancer Journal
- A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
- (2021) Mahesh Swaminathan et al. HAEMATOLOGICA
- Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation
- (2021) Gabriela Wiergowska et al. Pharmaceutics
- Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns
- (2021) Wei Guan et al. Experimental Hematology & Oncology
- Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression
- (2021) Kaosheng Lv et al. BLOOD
- The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
- (2021) Sunil K. Joshi et al. CANCER CELL
- The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach
- (2021) Abeer M. Al-Subaie et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety of FLT3 inhibitors in patients with acute myeloid leukemia
- (2021) Claudio Cerchione et al. Expert Review of Hematology
- The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
- (2021) Xinan Qiao et al. Blood Cancer Journal
- Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia
- (2021) Eman M.E. Dokla et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)
- (2021) Yong Chen et al. BIOORGANIC CHEMISTRY
- Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer
- (2021) Eman M.E. Dokla et al. BIOORGANIC CHEMISTRY
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
- (2021) Robert Roskoski Jr. PHARMACOLOGICAL RESEARCH
- FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
- (2021) Jarno Kivioja et al. Scientific Reports
- Advances in acute myeloid leukemia
- (2021) Laura F Newell et al. BMJ-British Medical Journal
- Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
- (2021) Mike Dennis et al. Blood Advances
- Effect of Food on the Pharmacokinetics of Quizartinib
- (2020) Jianke Li et al. Clinical Pharmacology in Drug Development
- Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation
- (2020) Grzegorz Helbig et al. ANNALS OF HEMATOLOGY
- Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
- (2020) Angela Joubert James et al. CLINICAL PHARMACOKINETICS
- Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
- (2020) Raghuveer Singh Mali et al. HAEMATOLOGICA
- Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
- (2020) Fabienne Kellner et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Identification of anticancer drugs associated with atrial fibrillation - analysis of the WHO pharmacovigilance database
- (2020) Joachim Alexandre et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
- (2020) Jannik Stemler et al. ANNALS OF HEMATOLOGY
- Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD
- (2020) Cong Liang et al. LEUKEMIA & LYMPHOMA
- Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
- (2020) Shanada Monestime et al. DRUGS IN R&D
- FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients With Acute Leukemias
- (2020) Jorge Vela-Ojeda et al. ARCHIVES OF MEDICAL RESEARCH
- Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
- (2020) Musa Yilmaz et al. Journal of Hematology & Oncology
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
- (2019) Christine M. McMahon et al. Cancer Discovery
- PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ Acute Myeloid Leukemia
- (2019) Xin He et al. BLOOD
- Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite
- (2019) Jianke Li et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies
- (2019) Ellen Weisberg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia
- (2019) Jun Ma et al. CLINICAL CANCER RESEARCH
- Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
- (2019) Kensuke Usuki et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Activation and Inactivation of the FLT3 Kinase: Pathway Intermediates and the Free Energy of Transition
- (2019) Guido Todde et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition
- (2019) Amal Kamal Abdel-Aziz et al. HAEMATOLOGICA
- Comparing apples with oranges: Studying LSD1 inhibitors in cellular assays
- (2019) Amal Kamal Abdel-Aziz et al. PHARMACOLOGICAL RESEARCH
- Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition inFLT3-Mutant Acute Myeloid Leukemia
- (2018) Xuejie Jiang et al. CLINICAL CANCER RESEARCH
- FLT3-TKD mutations associated to NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia
- (2018) Marielle Perry et al. Clinical Lymphoma Myeloma & Leukemia
- Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia
- (2018) Mark A. Gregory et al. EXPERIMENTAL HEMATOLOGY
- CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
- (2018) Hardikkumar Jetani et al. LEUKEMIA
- Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase
- (2018) Zhi-Hao Shi et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017
- (2018) Jingjing Yu et al. DRUG METABOLISM AND DISPOSITION
- Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
- (2018) George M. Burslem et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis
- (2017) Panagiotis Tsapogas et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways
- (2017) Li-Na Wang et al. LEUKEMIA & LYMPHOMA
- Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
- (2017) Catrin Roolf et al. MOLECULAR & CELLULAR PROTEOMICS
- FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
- (2017) Maria Larrosa-Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia
- (2017) Q Heydt et al. ONCOGENE
- From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
- (2017) Amal Kamal Abdel-Aziz et al. Frontiers in Pharmacology
- The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries
- (2016) Amal Kamal Abdel-Aziz et al. EXPERIMENTAL NEUROLOGY
- Dual modulation of MCL-1 and mTOR determines the response to sunitinib
- (2016) Mohamed Elgendy et al. JOURNAL OF CLINICAL INVESTIGATION
- ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia
- (2016) Mark A. Gregory et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia
- (2016) S. E. Meyer et al. Cancer Discovery
- The Adverse Effects of Sorafenib in Patients with Advanced Cancers
- (2015) Ye Li et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells
- (2015) C. Larrue et al. BLOOD
- Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells
- (2015) Tomohiro Hirade et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
- (2015) E Chang et al. LEUKEMIA
- FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
- (2015) C C Smith et al. LEUKEMIA
- Modulation of Imatinib Cytotoxicity by Selenite in HCT116 Colorectal Cancer Cells
- (2014) Amal Kamal Abdel-Aziz et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries
- (2014) Amal Kamal Abdel-Aziz et al. CHEMICO-BIOLOGICAL INTERACTIONS
- BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Cardiovascular Toxicity and Sorafenib
- (2013) Javier García-Lledó et al. AMERICAN JOURNAL OF THERAPEUTICS
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
- (2013) C. C. Smith et al. BLOOD
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
- (2013) Kerstin Maria Kampa-Schittenhelm et al. Molecular Cancer
- SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML
- (2012) H. Leischner et al. BLOOD
- Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
- (2012) C. J. Peer et al. CLINICAL CANCER RESEARCH
- Activity-based kinase profiling of approved tyrosine kinase inhibitors
- (2012) Daisuke Kitagawa et al. GENES TO CELLS
- Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
- (2012) A S Moore et al. LEUKEMIA
- Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study
- (2011) Keith T. Flaherty et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
- (2011) Paola Di Gion et al. CLINICAL PHARMACOKINETICS
- Protein-tyrosine Phosphatase DEP-1 Controls Receptor Tyrosine Kinase FLT3 Signaling
- (2011) Deepika Arora et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sunitinib
- (2009) Georgios S. Papaetis et al. BIODRUGS
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers
- (2009) Nancy L. Lewis et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose- and Time-Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus
- (2008) Yanfeng Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy
- (2008) Ju-Huei Chien et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now